HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cutanix distribution

This article was originally published in The Rose Sheet

Executive Summary

Copper peptide technology manufacturer ProCyte will market Cutanix Dramatic Relief product line to 3,000 physicians under exclusive distribution agreement, Redmond, Wash. firm announces. Two-year deal covers distribution rights for the medical and spa markets for all current and future Cutanix products formulated with Quadrinone. Patent-pending technology reduces inflammation associated with conditions such as rosacea and eczema, according to the company. Introduced in June 2002, Cutanix Dramatic Relief products include lotions for dry to normal skin, sensitive facial skin and oily and acne-prone skin, which retail for $45. Cutanix will launch Dramatic Relief body lotion, extra strength lotion and intensified eye serum in October...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS011387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel